Tejara Capital Ltd Makes New $825,000 Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Tejara Capital Ltd bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 28,781 shares of the specialty pharmaceutical company’s stock, valued at approximately $825,000. Tejara Capital Ltd owned about 0.09% of Collegium Pharmaceutical at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after acquiring an additional 175,892 shares during the last quarter. Penserra Capital Management LLC bought a new position in shares of Collegium Pharmaceutical in the third quarter worth about $757,000. Barclays PLC raised its stake in shares of Collegium Pharmaceutical by 152.2% in the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after acquiring an additional 45,291 shares during the last quarter. Sanctuary Advisors LLC raised its stake in shares of Collegium Pharmaceutical by 10.7% in the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after acquiring an additional 1,731 shares during the last quarter. Finally, FMR LLC raised its stake in shares of Collegium Pharmaceutical by 1,532.2% during the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock worth $1,459,000 after buying an additional 35,439 shares during the last quarter.

Insider Activity

In other news, CFO Colleen Tupper sold 10,445 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the completion of the transaction, the chief financial officer now owns 165,246 shares in the company, valued at $4,959,032.46. This represents a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total transaction of $742,909.50. Following the completion of the transaction, the executive vice president now owns 108,137 shares of the company’s stock, valued at $3,081,904.50. This trade represents a 19.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,961 shares of company stock worth $3,146,634 over the last quarter. 3.98% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Friday, January 10th. Piper Sandler dropped their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Stock Up 0.7 %

Shares of NASDAQ:COLL opened at $29.67 on Tuesday. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a market capitalization of $934.19 million, a PE ratio of 12.79 and a beta of 0.99. The company has a 50 day moving average price of $30.88 and a two-hundred day moving average price of $32.87.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.